Casdin Capital, LLC Buys Blueprint Medicines Corp, Twist Bioscience Corp, Gilead Sciences Inc, Sells Audentes Therapeutics Inc, Illumina Inc, Deciphera Pharmaceuticals Inc

• New Purchases: GILD, CRSP, ADVM, ZLAB, ALLO,
• Added Positions: BPMC, TWST, ADPT, AGIO, ALNY, BLUE, SAGE, DNLI, CDNA, ORTX, GRTS,
• Reduced Positions: CNST, ILMN, DCPH, NVTA, MGTA, STOK,
• Sold Out: BOLD,

For the details of Casdin Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/casdin+capital%2C+llc/current-portfolio/portfolio

1. Blueprint Medicines Corp (BPMC) - 1,550,000 shares, 10.23% of the total portfolio. Shares added by 64.89%
2. Sarepta Therapeutics Inc (SRPT) - 670,000 shares, 7.40% of the total portfolio.
3. Alnylam Pharmaceuticals Inc (ALNY) - 585,000 shares, 7.19% of the total portfolio. Shares added by 13.59%
4. Fate Therapeutics Inc (FATE) - 2,550,000 shares, 6.39% of the total portfolio.
5. Codexis Inc (CDXS) - 5,073,780 shares, 6.39% of the total portfolio.

Casdin Capital, LLC initiated holding in Gilead Sciences Inc. The purchase prices were between $62.63 and $80.22, with an estimated average price of $68.92. The stock is now traded at around $74.04. The impact to a portfolio due to this purchase was 1.48%. The holding were 175,000 shares as of .

Casdin Capital, LLC initiated holding in CRISPR Therapeutics AG. The purchase prices were between $33.68 and $62.53, with an estimated average price of $51.94. The stock is now traded at around $67.34. The impact to a portfolio due to this purchase was 1.28%. The holding were 266,430 shares as of .

Casdin Capital, LLC initiated holding in Adverum Biotechnologies Inc. The purchase prices were between $7.98 and $16.32, with an estimated average price of $11.72. The stock is now traded at around $24.31. The impact to a portfolio due to this purchase was 1.24%. The holding were 1,125,000 shares as of .

Casdin Capital, LLC initiated holding in Zai Lab Ltd. The purchase prices were between $39.1 and $62.9, with an estimated average price of $52.1. The stock is now traded at around $75.88. The impact to a portfolio due to this purchase was 1.1%. The holding were 190,000 shares as of .

Casdin Capital, LLC initiated holding in Allogene Therapeutics Inc. The purchase prices were between $18.22 and $28.25, with an estimated average price of $23.87. The stock is now traded at around $41.80. The impact to a portfolio due to this purchase was 1.1%. The holding were 500,000 shares as of .

Casdin Capital, LLC added to a holding in Blueprint Medicines Corp by 64.89%. The purchase prices were between $48.11 and $82.22, with an estimated average price of $64.89. The stock is now traded at around $76.32. The impact to a portfolio due to this purchase was 4.03%. The holding were 1,550,000 shares as of .

Casdin Capital, LLC added to a holding in Twist Bioscience Corp by 233.33%. The purchase prices were between $19.71 and $35.15, with an estimated average price of $26.78. The stock is now traded at around $40.55. The impact to a portfolio due to this purchase was 2.42%. The holding were 1,000,000 shares as of .

Casdin Capital, LLC added to a holding in Adaptive Biotechnologies Corp by 71.26%. The purchase prices were between $16.96 and $34.16, with an estimated average price of $27.98. The stock is now traded at around $44.57. The impact to a portfolio due to this purchase was 1.04%. The holding were 793,125 shares as of .

Casdin Capital, LLC added to a holding in Agios Pharmaceuticals Inc by 29.70%. The purchase prices were between $31.52 and $53.81, with an estimated average price of $46.42. The stock is now traded at around $48.00. The impact to a portfolio due to this purchase was 0.98%. The holding were 1,070,000 shares as of .

Casdin Capital, LLC added to a holding in Sage Therapeutics Inc by 67.39%. The purchase prices were between $26.15 and $77.24, with an estimated average price of $58.57. The stock is now traded at around $40.13. The impact to a portfolio due to this purchase was 0.5%. The holding were 385,000 shares as of .

Casdin Capital, LLC sold out a holding in Audentes Therapeutics Inc. The sale prices were between $59.83 and $60, with an estimated average price of $59.94.